Showing 8891-8900 of 9282 results for "".
- Lithera Changes Name to Neothetics, Inc.https://practicaldermatology.com/news/20140812-lithera_changes_name_to_neothetics_inc/2459146/In a move the company says is intended to stregthen its positioning as a clinical stage, specialty pharmaceutical company developing novel therapeutics for the aesthetics market, Lithera has changed its name to Neothetics, Inc. President and CEO of Neothetics George Mahaffey said, "Our ne
- Ultherapy Decolletage Treatment Now FDA Clearedhttps://practicaldermatology.com/news/20140707-ultherapy_dcolletage_treatment_now_fda_cleared/2459179/The FDA cleared Ulthera, Inc.'s Ulthera System for the non-invasive treatment of the chest to improve lines and wrinkles of the décolleté. The Ultherapy Décolletage Treatment uses the system's signature imaging and micro-focued ultr
- Jan Marini Skin Research Marks 20 Years of Innovationhttps://practicaldermatology.com/news/20140625-jan_marini_skin_research_marks_20_years_of_innovation/2459188/After 20 years, Jan Marini Skin Research (JMSR) continues to distinguish itself as a recognized leader in the professional skincare industry through its combined focus on results, new productinnovation and its commitment to clinical and medical validation. Robert Weiss, MD, conducted a st
- Dermatologist Lynette J. Margesson, MD Recognized as NAPW Woman of the Yearhttps://practicaldermatology.com/news/20140624-dermatologist_lynette_j_margesson_md_recognized_as_napw_woman_of_the_year/2459193/The National Association of Professional Women (NAPW) honored Lynette J. Margesson, MD of Danby & Margesson Dermatologists, as a 2014 Professional Woman of the Year. Dr. Margesson is recognized with this prestigious distinction for leadership in medicine.
- Valeant Pharmaceuticals Receives FDA Clearance For Restylane Silkhttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_receives_fda_clearance_for_restylane_silk/2459205/The FDA issued marketing clearance for Valeant Pharmaceuticals International, Inc.'s Restylane Silk Injectable Gel with 0.3% Lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of perio
- Cetaphil Launches the Gentle Power Campaignhttps://practicaldermatology.com/news/20140602-cetaphil_launches_the_gentle_power_campaign/2459221/The new Gentle Power Campaign for Cetaphil brands (Galderma) showcases the brand's products and demonstrates how women balance the demands of their day-to-day lives, just as Cetaphil products balance the daily demands on their skin. Stuart Raetzman, chief executive officer of Galderma L
- FDA to Require Warnings on Sunlamp Productshttps://practicaldermatology.com/news/20140530-fda_to_require_warnings_on_sunlamp_products/2459227/The FDA issued a final order reclassifying sunlamp products and ultraviolet (UV) lamps intended for use in sunlamp products from low-risk (class I) to moderate-risk (class II) devices. The order also requires that sunlamp products carry a visible black-box warning on the device
- iMatrix Launches New Web Marketing Services for Dermatologistshttps://practicaldermatology.com/news/20140520-imatrix_launches_new_web_marketing_services_for_dermatologists/2459235/iMatrix, division of Internet Brands, Inc. revealed new online marketing services for dermatologists, including marketing solutions, including professionally designed websites, social media management, video marketing, pay-per-click advertising, and a comprehensive SEO/SEM service called Dominato
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw
- Survey Finds Rosacea Sufferers' More Likely to be Judged Negatively Upon First Impressionhttps://practicaldermatology.com/news/20140428-survey_finds__rosacea_sufferers_more_likely_to_be_judged_negatively_upon_first_impression/2459251/A new survey by the National Rosacea Society finds that rosacea sufferers' are often judged negatively upon first impression. Shy, nervous, and stressed are the three words respondents used to describe their view of an individual with redness on their face, without knowing anything about them.